Open AccessTherapeutic outcome and safety of intralesional vitamin d3 in the treatment of cutaneous warts
Author(s) -
Bornali Dutta,
Anshu Maheswari,
Atul Bothra,
Pankaj Adhicari,
Seujee Das
Publication year - 2022
Publication title -
ip indian journal of clinical and experimental dermatology
Language(s) - English
Resource type - Journals
eISSN - 2581-4710
pISSN - 2581-4729
DOI - 10.18231/j.ijced.2022.010
Subject(s) - medicine , verruca vulgaris , dermatology , common warts , adverse effect , plantar warts , genital warts , vitamin , complete response , surgery , human papillomavirus , chemotherapy , cancer , cervical cancer
Cutaneous warts are a common but vexing condition with high recurrence rate and tendency to spread inspite of various therapeutic options. Intralesional immunotherapy is an attractive modality as it has an additional role of clearing both treated and distant warts by stimulating cell-mediated immunity against human papilloma virus. To evaluate efficacy and safety profile of intralesional Vitamin D3 formulation in the treatment of cutaneous warts. Patients with multiple cutaneous warts were injected intralesionally with Vitamin D3 (0.2 ml, 15 mg/ml) at an interval of 2 weeks for maximum of 4 sessions, and patients were followed up for 6 months. : Of the 106 patients included, complete clearance was seen in 26 (76.4 %) patients of verruca vulgaris, 20 (66.6 %) of palmoplantar warts, 18 (100 %) of plane warts, 6 (50 %) of genital and filiform warts each. Moderate response was seen in 14 (13.2%) patients while mild response was seen in 6 (5.7 %) patients. No response was seen in 10 (9.4 %) patients. No serious adverse effects were reported. : Intralesional Vitamin D3 is effective, safe, cheap and long lasting modality with a short downtime for the treatment of multiple cutaneous warts.